Methotrexate: shall we split up? Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. https://t.co/txCIkgtvzP https://t.co/Mk8FLy4jO3

• Methotrexate: shall we split up? | RheumNow

How do we manage difficult discussions about pregnancy in RA? Most rheums know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though... https://t.co/cXtqqVv6fp https://t.co/k5afTUKYf8

• How do we manage difficult discussions about pregnancy in RA? | RheumNow

L20 at #ACR23 Phase 3 RCT of #Telitacicept vs. placebo in #RA ☝🏻B-cell neutralization by targeting BlyS and APRIL ✅ better ACR20 and 50 response at W24 ✅ favorable structural response ✅ good safety profile ❓ few seronegative patients A new small molecule to treat #RA? PAJ https://t.co/fyrqAya41e

#ACR23 #EdLovering presenting on association b/w #RA, #CVD & #Dementia: 👉🏻CVD is not a signif mediator b/w RA &Dementia 👉🏻 signif synergy b/w RA & CVD on dementia (HR 2.45 vs those w/o RA&CVD) 👉🏻 ⬆️ risk of dementia in RA mostly in people with RA+CVD #Mayoclinicrheumatology https://t.co/5kqs3HAACn

The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease #ACR23 The metabolomics facility was established recently at the @UHN @UofT @SchroederInst and we are already seeing the results. @KrembilF @CRASCRRheum @UofTRheum https://t.co/Azxq3k8w5g

Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation! #ACR23 https://t.co/P7keAoOX7M

🔥 HOT OFF THE PRESS for #ACR23 Effectiveness of a fourth dose of #COVID19 mRNA #vaccine in patients with systemic autoimmune rheumatic diseases using DMARDs: an emulated target trial https://t.co/bvc75BP4aG @zach_wallace_md @jeffsparks https://t.co/CAlgjvUr9X

Something to listen to on the way home from #ACR23 The last episode in a 4 part series on the environment and autoimmunity What does silica exposure have to do with autoimmunity? https://t.co/2Vqi22xqCw

Nipocalimab (say it a couple of times) is a FcRn (neonatal Fc receptor) inhibitor. In short promotes degradation of IgG incl autoantibodies (and investigated in myasthenia). Prof Taylor presents that it might work in CCP high titer RA at #ACR23. #ACRambassador @ACRheum https://t.co/DqlsOv7AVI

Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23 Feasible after early remission induction https://t.co/WwiNp8WKDC

Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer .Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs

Just presented at #ACR23 by Dr Jennifer Hanberg @Jen_LS_Hanberg and published at @TheLancetRheum.! Effectiveness of 4th mRNA COVID dose on breakthrough infection @zach_wallace_md https://t.co/PXc2THn217

Chikungunya - takeaway points 🪔Acute arthritis in large joints , polyarthritis and tenosynovitis in hands 🪔 Associated with travel history to Africa/Asia/Asia Pacific 🪔<5% develop chronic arthritis #ACR23 #ACRambassador https://t.co/yzZDpy70i3

Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases Pregnant women with ARDs and APS face significantly increased risks of CVEs. This increased risk is often attributed to ARDs, its medications or comorbidities associated with it. https://t.co/KwMEwlr7Af https://t.co/vDt4B8jtt6

• Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases | RheumNow